Navigation Links
ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/6/2008

7 33,007 Cost of products sold 5,447 3,253 15,864 9,943 Gross profit margin 13,715 9,007 43,003 23,064 Costs and expenses:

Research and development 11,572 6,066 32,492 23,826

Selling, general, and

administrative 11,503 8,997 46,603 37,357 Total costs and expenses 23,075 15,063 79,095 61,183 Loss from operations (9,360) (6,056) (36,092) (38,119) Interest income 655 615 2,141 1,879 Interest expense (1,151) (992) (4,270) (2,179) Net loss $ (9,856) $ (6,433) $ (38,221) $ (38,419) Net loss per common share,

basic and diluted $ (0.30) $ (0.25) $ (1.29) $ (1.48) Shares used in computing

net loss per common share,

basic and diluted 32,884 26,074 29,621 26,011

ISTA Pharmaceuticals, Inc.

Summary of Consolidated Balance Sheets Data

(in thousands)

(unaudited)

December 31, December 31,

2007 2006 Cash and short-term investments $ 46,140 $ 38,934 Restricted cash 2,400 5,600 Working capital 32,686 27,998 Total assets 71,716 59,743 Total stockholders' deficit (1,308) (4,559)


'/>"/>
SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ADVENTRX Pharmaceuticals to Report Fourth Quarter and Year End 2007 Results
2. Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations
3. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
4. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
5. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
6. SGX Pharmaceuticals Schedules Teleconference and Webcast for Fourth Quarter and Full Year 2007 Results
7. NPS Pharmaceuticals to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
8. NuRx Pharmaceuticals Retains Russo Partners for Investor Relations, Corporate Communications Counsel
9. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
10. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
11. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... IN (PRWEB) , ... July 01, 2015 , ... Apex ... 2015 BIO International Convention in Philadelphia, PA. , The presentation took place ... and outlined the plans for the development of APX3330 for the treatment of pancreatic ...
(Date:7/1/2015)...  UCB, a multinational biopharmaceutical company, and Genpact ... designing, transforming, and running intelligent business operations, have ... their close collaboration in driving transformation that achieved ... (GBS) finance organization. The Aecus Innovation ... together effectively to embrace the innovative promise of ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... 12 to take part in the first half of “Integrative Biotechnology,” an applied ... partnership established in summer 2014, this course combines students from both universities and ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... hosting a webinar to provide advanced scientific research into new classes of Nanoscale ... and energy. Touted as 'the wonder material of the 21st Century' by ...
Breaking Biology Technology:Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4
... announced today the availability of the world,s first clinical guidelines to ... cells to treat disease. , ... Broomfield, CO (PRWEB) ... ASCTA ) announced today the availability of the world,s first clinical ...
... illustrate potential cost effective approach for, ... Symbol: RVX,CALGARY and ATLANTA, May 19 /PRNewswire-FirstCall/ - ... pleased to announce today that it has made ... (R&D) program for inflammatory diseases. Two new patent ...
... Therapeutic for IBD with Novel Mode of ActionMOUNTAIN ... Inc., today announced that data from the company,s ... Crohn,s disease Trial) Phase II/III clinical trial of ... will be presented in an oral session at ...
Cached Biology Technology:Physician's Organization Makes History by Publishing U.S.'s First Adult Stem Cell Guidelines (ASCTA Drives Safe Stem Cell Practices) 2Physician's Organization Makes History by Publishing U.S.'s First Adult Stem Cell Guidelines (ASCTA Drives Safe Stem Cell Practices) 3Physician's Organization Makes History by Publishing U.S.'s First Adult Stem Cell Guidelines (ASCTA Drives Safe Stem Cell Practices) 4Resverlogix's Success in Inflammation Program Results in 2 Patents Filed 2Resverlogix's Success in Inflammation Program Results in 2 Patents Filed 3ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 2ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 3ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 4ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 5
(Date:6/16/2015)... QUEBEC CITY , June 16, 2015 /CNW ... announce their partnership centralized around the incorporation of ... mobile point-of-care diagnostic laboratory, the Mo-POD™. This unprecedented ... the BIO International Conference at the ... from June 15 th to ...
(Date:6/15/2015)... According to a new market ... Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & ... MarketsandMarkets, The Natural Language Processing Market is expected to ... for the forecast period 2015-2020. Browse ... igures spread   through 155 P ages and ...
(Date:6/11/2015)... June 11, 2015 Daon, a global ... that its IdentityX Mobile Authentication Platform v4.0 has ... Alliance is an industry consortium launched in 2013 ... simpler, stronger authentication.  In order to receive certification, ... rigorous series of tests that measure compliance and ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2
... are working to improve understanding about obesity and cancer. ... Applied Physiology, Nutrition, and Metabolism , is the first ... than estimates like body mass index (BMI) or waist ... cancer risk in aging populations. Findings emphasize the negative ...
... publishes "Assessing Dangerous Climate Change: Required Reductions of Carbon ... from James Hansen and colleagues, and announces call for ... Research article assesses climate impacts of global warming using ... energy imbalance and simple representations of the global carbon ...
... edges of most public forests in Oregon and Washington more ... the U.S. Forest Service Pacific,s Northwest (PNW) Research Station has ... structures at the fringes of public forests, is the first ... and after the enactment of land use laws. The findings ...
Cached Biology News:Radiographic imaging exposes relationship between obesity and cancer 2Assessing dangerous climate change and call for climate change response papers 2Development near Oregon, Washington public forests 2
Mouse monoclonal antibody raised against a partial recombinant ACTN4. NCBI Entrez Gene ID = ACTN4...
Rabbit polyclonal antibody to GluR2...
... Blocker Array II can be used to ... various proteins and sera that are commonly ... The array contains spots for 19 different ... Determination of antibody crossreactivity and species specificity, ...
... sufficient materials for 1,464 array sample elements. , ... , Blocker BSA in PBS (10X): 50 ... 10 g , BupH Phosphate Buffered ... 2 x 10 ml ampules , SuperSignal West ...
Biology Products: